Research location
Bari
Italy
Advertisement
Research activity in Bari
ItalyCureCurrent currently publishes aggregate city-level research activity for this location: 311 trials and 323 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Bari
311 linked trials · page 2 of 7Initiation of Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin, in ItalyNCT06268808 · 2024-07-19 · 1 site observation
COMPLETED
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryNCT06161441 · 2024-07-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Effects of L-arginine and Liposomial Vitamin C on Severe Copd Patients Undergoing Pulmonary Rehabilitation.NCT06439875 · 2024-07-16 · 1 site observation
COMPLETED
Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung CancerNCT05718297 · 2024-06-07 · 1 site observation
WITHDRAWN
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and DurvalumabNCT06211036 · 2024-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)NCT05925530 · 2024-02-22 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyNCT05979311 · 2024-02-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard TreatmentNCT06151574 · 2024-02-09 · 1 site observation
ACTIVE_NOT_RECRUITING
REspiratory reHABilitation and PSYchiatric ComorbiditiesNCT06229600 · 2024-01-02 · 1 site observation
COMPLETED
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsNCT06120491 · 2023-11-21 · 1 site observation
ACTIVE_NOT_RECRUITING
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaNCT06097728 · 2023-11-09 · 1 site observation
ACTIVE_NOT_RECRUITING
Supporting Mental Health in Daily Life After the Diagnosis of Multiple SclerosisNCT06403631 · 2023-11-06 · 1 site observation
COMPLETED
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.NCT05984277 · 2023-10-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)NCT06041269 · 2023-08-31 · 1 site observation
ACTIVE_NOT_RECRUITING
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 InhibitorsNCT05671510 · 2023-06-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes SubtypesNCT06120556 · 2023-06-10 · 1 site observation
COMPLETED
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)NCT05607550 · 2023-06-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 1 site observation
TERMINATED
Platelet Rich Plasma (PRP) as Terapeutical Option in Erectil Disfunction (DE)NCT06768177 · 2023-04-01 · 1 site observation
ENROLLING_BY_INVITATION
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).NCT05742802 · 2023-03-06 · 1 site observation
COMPLETED
Relationship Between Glycemic Control and Irisin in Type 2 Diabetic Patients With Sarcopenic or Non-sarcopenic ObesityNCT05908812 · 2023-02-01 · 1 site observation
UNKNOWN
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512 · 2022-10-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTENCT05171075 · 2022-09-27 · 1 site observation
TERMINATED
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung CancerNCT05388669 · 2022-08-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286 · 2022-07-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382299 · 2022-07-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Tracking Treatment Pathways in Adult Patients With Hyperkalemia.NCT05408039 · 2022-07-14 · 1 site observation
COMPLETED
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyNCT05338970 · 2022-07-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.NCT05785208 · 2022-06-28 · 1 site observation
UNKNOWN
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTENCT05171049 · 2022-05-05 · 1 site observation
TERMINATED
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR AlterationNCT05253807 · 2022-04-29 · 1 site observation
COMPLETED
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast CancerNCT05212701 · 2022-04-19 · 1 site observation
WITHDRAWN
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related EpilepsyNCT05323734 · 2022-04-01 · 1 site observation
COMPLETED
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast CancerNCT05169567 · 2022-03-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsNCT05215340 · 2022-03-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Study in Adult Patients With Moderate to Severe AsthmaNCT04886999 · 2022-02-24 · 1 site observation
COMPLETED
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionNCT05120349 · 2022-02-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.NCT05158387 · 2022-02-07 · 1 site observation
COMPLETED
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung CancerNCT04774380 · 2021-11-11 · 1 site observation
COMPLETED
Use of nMoABs for the Treatment of COVID-19 in Patients With HM.NCT04932967 · 2021-09-30 · 1 site observation
COMPLETED
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLCNCT04919811 · 2021-09-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Open-Label Surufatinib in European Patients With NETNCT04579679 · 2021-08-13 · 1 site observation
TERMINATED
Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target TherapyNCT05754502 · 2021-07-27 · 1 site observation
UNKNOWN
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)NCT04895358 · 2021-06-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Alectinib in Neo-adjuvant Treatment of Stage III NSCLCNCT05015010 · 2021-05-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCNCT04821622 · 2021-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid ArthritisNCT04871919 · 2021-05-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Sarcopenic Obesity in Liver Transplanted PatientsNCT05029713 · 2021-05-10 · 1 site observation
COMPLETED
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)NCT04736706 · 2021-04-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Breathomics: May it Become an Affordable, New Tool for Early Diagnosis and Screening of Lung Cancer?NCT06034730 · 2021-04-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.